Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NARINDER SAINI

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1356420665
CMS profile
1142372
Location
SPRINGFIELD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$12.83

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $12.83 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Alkermes, Inc. $12.83 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NARINDER SAINI

NPI 1356420665 · CMS profile ID 1142372

Allopathic & Osteopathic Physicians / Internal Medicine

SPRINGFIELD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $12.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $12.8304/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686626397 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12.83 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $9,450.00 1
PY2024 Principal investigator $23,855.10 5
PY2023 Recipient $11,082.59 1
PY2023 Principal investigator $9,599.85 7
PY2022 Recipient $3,897.05 1
PY2022 Principal investigator $1,244,253.27 83
PY2021 Recipient $434,945.60 1
PY2021 Principal investigator $917,788.30 69
PY2020 Recipient $15,112.10 3
PY2020 Principal investigator $408,488.40 195
PY2019 Recipient $586.07 1
PY2019 Principal investigator $552,873.53 77

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

84 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Partner Therapeutics, Inc. $2,000.00 12/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517811
Principal investigator 1 Roche Diagnostics Operations, Inc. $8,896.50 12/07/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915609411
Principal investigator 1 Roche Diagnostics Operations, Inc. $2,400.00 12/07/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915609641
Principal investigator 1 Roche Diagnostics Operations, Inc. $1,500.00 12/07/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915610223
Principal investigator 1 Vanda Pharmaceuticals Inc. $100.00 12/02/2022 Non-covered Recipient Entity
WELLNOW URGENT CARE AND RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 951893771
Principal investigator 1 Partner Therapeutics, Inc. $3,000.00 11/18/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517617
Principal investigator 1 Partner Therapeutics, Inc. $150.00 11/18/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517853
Principal investigator 1 Vanda Pharmaceuticals Inc. $350.00 11/16/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 951893523
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,099.15 11/03/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933402193
Principal investigator 1 Vanda Pharmaceuticals Inc. $7,449.00 11/02/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 951893451
Principal investigator 1 Roche Diagnostics Operations, Inc. $33.93 10/28/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915609355
Principal investigator 1 Roche Diagnostics Operations, Inc. $441.00 10/28/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915609757
Principal investigator 1 Roche Diagnostics Operations, Inc. $350.00 10/07/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915609905
Principal investigator 1 Roche Diagnostics Operations, Inc. $63.00 10/05/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915609443
Principal investigator 1 Roche Diagnostics Operations, Inc. $252.00 10/05/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915610009
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,400.00 10/04/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 951893055
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $7,012.91 09/15/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933400077
Principal investigator 1 GlaxoSmithKline, LLC. $20,051.18 09/06/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 944016845
Principal investigator 1 Roche Diagnostics Operations, Inc. $55,092.40 09/01/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915609597
Principal investigator 1 Roche Diagnostics Operations, Inc. $63.00 08/24/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915608391
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $9,106.32 08/11/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933396793
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,171.95 07/21/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933393805
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,530.00 07/14/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933393517
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,530.00 07/14/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933393527
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $16,935.03 06/23/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933390841
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,000.00 06/16/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933390239
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $7,440.95 05/26/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933388171
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $6,967.21 05/26/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933388177
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $4,761.87 05/26/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933388201
Principal investigator 1 Partner Therapeutics, Inc. $2,900.00 05/06/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517743
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,302.30 04/14/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933384273
Principal investigator 1 GlaxoSmithKline, LLC. $8,271.48 04/13/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 944016839
Principal investigator 1 Vanda Pharmaceuticals Inc. $10,724.00 04/13/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 951891063
Principal investigator 1 Partner Therapeutics, Inc. $27,734.20 04/08/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517595
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $176.80 03/24/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933382845
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $200.00 03/17/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933382505
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,530.00 03/17/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933382517
Principal investigator 1 Vanda Pharmaceuticals Inc. $11,976.00 03/16/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 951890567
Principal investigator 1 Roche Diagnostics Operations, Inc. $113,941.10 03/09/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915609875
Principal investigator 1 Partner Therapeutics, Inc. $26,934.70 02/25/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517453
Principal investigator 1 Partner Therapeutics, Inc. $28,403.70 02/25/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517525
Principal investigator 1 Partner Therapeutics, Inc. $28,514.20 02/25/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517563
Principal investigator 1 Partner Therapeutics, Inc. $28,555.80 02/25/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517599
Principal investigator 1 Partner Therapeutics, Inc. $25,888.20 02/25/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517647
Principal investigator 1 Partner Therapeutics, Inc. $28,514.20 02/25/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517759
Principal investigator 1 Partner Therapeutics, Inc. $27,028.30 02/25/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517761
Principal investigator 1 Partner Therapeutics, Inc. $28,555.80 02/25/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517839
Principal investigator 1 Partner Therapeutics, Inc. $27,695.20 02/25/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517841
Principal investigator 1 Partner Therapeutics, Inc. $27,847.30 02/25/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517875
Principal investigator 1 Partner Therapeutics, Inc. $28,165.80 02/25/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517877
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $9,997.14 02/24/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933380957
Principal investigator 1 Partner Therapeutics, Inc. $27,258.30 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517449
Principal investigator 1 Partner Therapeutics, Inc. $28,514.20 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517451
Principal investigator 1 Partner Therapeutics, Inc. $28,514.20 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517477
Principal investigator 1 Partner Therapeutics, Inc. $28,555.80 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517503
Principal investigator 1 Partner Therapeutics, Inc. $28,455.70 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517505
Principal investigator 1 Partner Therapeutics, Inc. $12,881.70 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517539
Principal investigator 1 Partner Therapeutics, Inc. $27,626.30 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517561
Principal investigator 1 Partner Therapeutics, Inc. $28,555.80 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517639
Principal investigator 1 Partner Therapeutics, Inc. $27,597.70 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517641
Principal investigator 1 Partner Therapeutics, Inc. $26,209.30 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517643
Principal investigator 1 Partner Therapeutics, Inc. $26,057.20 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517645
Principal investigator 1 Partner Therapeutics, Inc. $27,077.70 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517697
Principal investigator 1 Partner Therapeutics, Inc. $28,514.20 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517699
Principal investigator 1 Partner Therapeutics, Inc. $28,514.20 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517731
Principal investigator 1 Partner Therapeutics, Inc. $2,975.00 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517733
Principal investigator 1 Partner Therapeutics, Inc. $27,961.70 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517757
Principal investigator 1 Partner Therapeutics, Inc. $28,555.80 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517799
Principal investigator 1 Partner Therapeutics, Inc. $28,282.80 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517801
Principal investigator 1 Partner Therapeutics, Inc. $28,555.80 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517837
Principal investigator 1 Partner Therapeutics, Inc. $28,224.30 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517873
Principal investigator 1 Partner Therapeutics, Inc. $28,514.20 02/16/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517915
Principal investigator 1 Partner Therapeutics, Inc. $295.00 02/15/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517729
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,000.00 02/10/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933380039
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,938.75 02/10/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933380047
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $6,000.00 02/10/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933380409
Principal investigator 1 Partner Therapeutics, Inc. $75.00 02/04/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517871
Principal investigator 1 Roche Diagnostics Operations, Inc. $11,500.00 02/02/2022 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
RD006118 No dispute reported 06/30/2026 915608737
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,550.00 01/19/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 951889435
Principal investigator 1 Partner Therapeutics, Inc. $1,350.00 01/11/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517797
Principal investigator 1 Partner Therapeutics, Inc. $3,750.00 01/11/2022 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 916517869
Principal investigator 1 Eli Lilly and Company $451.00 01/10/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 917845207
Principal investigator 1 Eli Lilly and Company $5,938.00 01/10/2022 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 917848047
Recipient Celltrion, Inc. $3,897.05 01/05/2022 Covered Recipient Physician CT-P59 3.2 No dispute reported 06/30/2026 910662345